Recent studies have centered on the overlap of GLP|GIP|GCGR activator therapies and dopamine neurotransmission. While GLP stimulators are widely employed for managing type 2 diabetes mellitus, their unexpected effects on reward circuits, specifically influenced by DA pathways, are attracting substantial focus. This article provides a brief examinat